

5 March 2026

FIRST TRIAGE PLUS TESTS ORDERED FROM TOWNSVILLE

DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) announces today that after 11 referrals for Cxbladder were sent to patients last week, the first Triage Plus test has now been ordered by Townsville University Hospital, according to an agreed clinical pathway. The consultant urologists at Townsville University Hospital have developed nurse-led clinical protocols for hematuria evaluation¹ with Triage Plus and for NMIBC² surveillance with Monitor.

Townsville University Hospital is a leading care provider in the North Queensland region serving a local population of 250,000 and a referral catchment of 700,000. The adoption of Cxbladder genomic biomarker testing is intended to streamline urological care as part of their “nurse-led services” to ensure that clinical resources are prioritized for those who require further evaluation while giving all patients the best experience possible.

Cxbladder Triage Plus will be used to risk stratify patients presenting to urologic care with hematuria. The protocol will allow clinicians to de-intensify the workup of those with a low risk of bladder cancer, reducing the need for further invasive testing, while identifying and prioritizing those who require immediate care. In surveillance for recurrent bladder cancer, Cxbladder Monitor will be used to help safely reduce the frequency of cystoscopy required in NMIBC patients, improving patient comfort and supporting increased adherence to their regularly scheduled surveillance appointments.

Triage Plus is a multi-modal (RNA and DNA) urine-based genomic test with substantially improved performance characteristics when contrasted with first generation Cxbladder tests for hematuria evaluation, Triage and Detect. With the recent publication of the DRIVE study³ in the *Journal of Urologic Oncology* providing an independent clinical validation, Triage Plus builds on the performance of Cxbladder Triage, a test now included in the American AUA/SUFU Microhematuria Guideline⁴, supported with “Grade A” evidence from a randomized controlled trial (STRATA⁵). In addition to its superior clinical value, Triage Plus delivers greater health economic value for institutions and payers, and positively impacts revenue and margin per test for Pacific Edge.

From 2023, Cxbladder Monitor has been recognized in the European Association of Urology (EAU) NMIBC Guideline which is influential among Australian urologists. The utility of the test

¹ Blood in urine, the most common symptom of bladder cancer and often the first sign.

² NMIBC is non-muscle invasive bladder cancer.

³ Savage et al. (2025). Diagnostic performance of Cxbladder Triage Plus for the identification and stratification of patients at risk for urothelial carcinoma: The multicenter, prospective, observational DRIVE study. *Urologic oncology*, S1078-1439(25)00405-3. Advance online publication. <https://doi.org/10.1016/j.urolonc.2025.10.008>

⁴ Barocas et al. (2025). Updates to Microhematuria: AUA/SUFU Guideline (2025). *The Journal of urology*, 213(5), 547–557. <https://doi.org/10.1097/JU.0000000000004490>.

⁵ Lotan et al. (2024). A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients With Microhematuria. The Safe Testing of Risk for Asymptomatic Microhematuria Trial. *The Journal of Urology* Vol 212(1) 41-51.

is further supported by real-world evidence. In 2025 Royal Perth Hospital conducted a clinical validation study⁶ and Northern Health in Melbourne conducted a clinical utility study⁷. These studies demonstrated the effectiveness and safety of Cxbladder Monitor as a non-invasive alternative in the surveillance for recurrent bladder cancer. Notably, the findings highlight a range of clinical and operational benefits from using Monitor, including the significant potential for it to optimize bladder cancer surveillance programs, reducing healthcare costs, substantially lifting patient satisfaction, and improving overall healthcare system efficiency.

Pacific Edge CEO Peter Meintjes said “We’re delighted to be supporting Townsville University Hospital as they implement Cxbladder testing as part of their nurse-led services for hematuria patients and non-muscle invasive bladder cancer surveillance patients. The benefits of our non-invasive genomic urine tests are well established, but having Cxbladder implemented by nurses is a great way to reduce the volume of unnecessary cystoscopies, helping clinical teams streamline resource utilization and improve day-to-day patient care for the patients most in need.”

The initiation of Cxbladder testing at Townsville University Hospital marks the continued adoption of the Cxbladder suite in Australia. Globally Cxbladder is now available in the US, Australasia, and Israel and in select markets throughout Asia and South America. In the US, the test has been used by over 5,000 urologists who have ordered more than 130,000 tests. In New Zealand, Cxbladder is accessible to around 70% of the population via public healthcare and every resident has the option of ordering the test online.

Pacific Edge: www.pacifiedgedx.com

Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA.

Cxbladder: www.cxbladder.com

Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification of urothelial cancer in patients presenting with hematuria and those being monitored for recurrent disease. The tests help improve the overall patient experience, while prioritizing time and clinical resources to optimize practice workflow and improve efficiency.

⁶ Magee D, Tharakan N, Yuiminaga Y. Validation of Cxbladder® Triage and Monitor as an Adjunct to Urothelial Carcinoma Diagnosis and Surveillance in a Single Centre. Res Rep Urol. 2025 Mar 18;17:87-94. doi: 10.2147/RRU.S516994. PMID: 40129475; PMCID: PMC11930626

⁷ Guduguntla et al. (2025) A novel bladder cancer surveillance schedule using bladder Cx for patients on annual surveillance. BJUI Compass. 2025;6(1).

Supported by over 20 years of research, Cxbladder's evidence portfolio extends to more than 25 peer reviewed publications, and Cxbladder Triage is now included in the American Urological Association's Microhematuria Guideline. To drive increased adoption and improved patient health outcomes, Cxbladder is the focal point of numerous ongoing and planned studies designed to generate further clinical utility evidence.

Cxbladder is available in the US, Australasia, and Israel and in markets throughout Asia and South America. In the US, the test has been used by over 5,000 urologists who have ordered more than 130,000 tests. In New Zealand, Cxbladder is accessible to around 70% of the population via public healthcare and all residents have the option of buying the test online.

For personal use only